Roche Bets on Glofitamab in Phase 3 Trial for Relapsed Mantle Cell Lymphoma
Clinical Design and Timeline
Roche Holding (ROG.SW)-sponsored GLOBRYTE is a global Phase 3 trial randomizing 182 patients with relapsed/refractory mantle cell lymphoma (MCL) who have received prior systemic therapy with a BTK inhibitor, in a 1:1 ratio. Glofitamab (Glofitamab-gxbm) is administered in 12 cycles every 21 days following obinutuzumab pretreatment, while the control group receives either mabthera (rituximab, CD20) + bendamustine or lenalidomide (Revlimid) + rituximab. The primary endpoint is progression-free survival (PFS) assessed by an independent review committee, and secondary endpoints include complete response rate, objective response rate, and overall survival. According to ClinicalTrials.gov, the trial is ongoing, with primary completion expected in August 2027 and overall completion in March 2028.
Mechanism of Action and Clinical Differentiation
Glofitamab is a bispecific T-cell engaging antibody that simultaneously binds CD20 on B cells and CD3 on T cells. It recruits T cells to the tumor site to induce cytotoxic responses. The fixed 12-cycle treatment duration distinguishes it from oral therapies that require continuous dosing until disease progression. However, to manage cytokine release syndrome (CRS), a stepwise dose escalation, obinutuzumab pretreatment, and tocilizumab (Actemra, IL-6 receptor antagonist) as needed are used. Thus, efficacy alone is not sufficient; the burden of hospitalization and monitoring, as well as the convenience of fixed-duration treatment, will influence real-world adoption.
Competitive Landscape and Market Potential
In this patient population, Eli Lilly (LLY)'s Jaypirca (pirtobrutinib, non-covalent BTK inhibitor) and Gilead Sciences (GILD)-affiliated Kite's Tecartus (brexucabtagene autoleucel, CD19 CAR-T) are established key competitors. The FDA granted Jaypirca accelerated approval on January 27, 2023, for relapsed/refractory MCL after BTK inhibitor therapy, and Brukinsa (zanubrutinib, BTK) holds an indication for MCL after prior therapy. GLOBRYTE excludes CAR-T experienced patients, targeting those who may receive the therapy before or without access to cell therapy. The global MCL market is projected to grow from USD 2.71 billion in 2025 to USD 4.28 billion in 2031, making late-line treatment share commercially valuable.
Regulatory History and Investment Implications
The FDA granted Glofitamab accelerated approval on June 15, 2023, for relapsed/refractory DLBCL beyond third-line, and the EMA granted conditional approval on July 7, 2023, which was converted to full approval on May 8, 2025. These approvals are for large B-cell lymphoma, not MCL, so a positive GLOBRYTE Phase 3 result and a separate MCL indication review are required. In 2025, the FDA Oncologic Drugs Advisory Committee voted 8 to 1 against the applicability of DLBCL combination therapy data to U.S. patients, highlighting regulatory challenges regarding regional representativeness and survival benefit. As the trial is still in the pre-result phase, the key value drivers will be PFS improvement over the control group and a balanced safety profile, including CRS management.
GLOBRYTE is testing glofitamab monotherapy directly against rituximab + bendamustine or rituximab + lenalidomide in a 182-patient Phase 3 trial to assess its potential for integration into MCL standard of care. With primary completion expected in August 2027, it is more of a mid-to-long-term asset for label expansion rather than a short-term stock catalyst. Success would allow Roche to secure a fixed-duration CD20×CD3 therapy to compete with Jaypirca and Tecartus in the USD 2.71 billion 2025 global MCL market. For investigators, the relative PFS and CRS management data of bispecific antibodies compared to BTK inhibitors will be key evidence. The 2025 FDA ODAC 8-1 negative vote on DLBCL combination therapy highlights regional representativeness and overall survival interpretation as critical risk factors for U.S. registration strategy.
Source: ClinicalTrials.gov (api_ct)